GlaxoSmithKline (GSK) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral
October 26, 2017 4:42 AM EDTBofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral.
Analyst Graham Parry says the valuation is not demanding and sees growing uncertainties likely capping P/E recovery into 2018 stemming from margin pressure and consensus EPS reductions on Advair generics... More



